- Home
- HUYA vs MDXG Comparison
HUYA vs MDXG Comparison
Compare HUYA & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HUYA | MDXG |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 572.2M | 607.7M |
| IPO Year | 2018 | 2007 |
Fundamental Metrics
Financial Performance| Metric | HUYA | MDXG |
|---|---|---|
| Price | $2.41 | $4.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $3.50 | ★ $9.00 |
| AVG Volume (30 Days) | 724.3K | ★ 1.2M |
| Earning Date | 05-12-2026 | 04-29-2026 |
| Dividend Yield | ★ 81.37% | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,630,000.00 |
| Revenue This Year | $14.08 | N/A |
| Revenue Next Year | $6.11 | $13.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.99 |
| 52 Week Low | $2.15 | $3.03 |
| 52 Week High | $4.93 | $7.99 |
Technical Indicators
Market Signals| Indicator | HUYA | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 48.46 | 68.61 |
| Support Level | $2.15 | $3.50 |
| Resistance Level | $2.54 | $5.38 |
| Average True Range (ATR) | 0.08 | 0.16 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 70.39 | 79.72 |
Price Performance
Historical ComparisonAbout HUYA HUYA Inc. American depositary shares each representing one ordinary share
Huya officially became independent in 2016 and is headquartered in Guangzhou. It operates a live streaming platform focused on games, esports, and interactive entertainment, and also provides game-related services such as distribution and in-game item sales. Its main livestreaming platforms include Huya Live in China and Nimo TV outside of China. Huya is a subsidiary of Tencent, which owned 67% of its equity stake and held 95% of the voting power, as of the end of 2025.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.